Evotec SE ADR (NASDAQ:EVO) — Market Cap & Net Worth
Market Cap & Net Worth: Evotec SE ADR (EVO)
Evotec SE ADR (NASDAQ:EVO) has a market capitalization of $1.15 Billion ($1.15 Billion) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8301 globally and #2430 in its home market, demonstrating a 0.62% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Evotec SE ADR's stock price $3.23 by its total outstanding shares 355209170 (355.21 Million). Also see Evotec SE ADR assets under control for a full breakdown of the balance sheet.
Evotec SE ADR Market Cap History: 2015 to 2026
Evotec SE ADR's market capitalization history from 2015 to 2026. Data shows growth from $801.88 Million to $578.99 Million (3.69% CAGR). Also see cash flow conversion of Evotec SE ADR for how efficiently the company converts equity into cash flow.
Index Memberships
Evotec SE ADR is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.04% | #240 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #900 of 3165 |
Weight: Evotec SE ADR's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Evotec SE ADR Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Evotec SE ADR's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check EVO stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.44x
Evotec SE ADR's market cap is 1.44 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.38 Billion | $164.51 Million | $27.53 Million | 8.40x | 50.22x |
| 2017 | $2.85 Billion | $257.63 Million | $24.26 Million | 11.06x | 117.51x |
| 2018 | $3.54 Billion | $375.40 Million | $84.17 Million | 9.42x | 42.02x |
| 2019 | $4.56 Billion | $446.44 Million | $38.16 Million | 10.22x | 119.63x |
| 2020 | $6.52 Billion | $500.92 Million | $6.28 Million | 13.01x | 1038.10x |
| 2021 | $8.44 Billion | $618.03 Million | $215.51 Million | 13.65x | 39.15x |
| 2022 | $2.87 Billion | $751.45 Million | -$175.66 Million | 3.82x | N/A |
| 2023 | $4.17 Billion | $781.43 Million | -$83.91 Million | 5.33x | N/A |
| 2024 | $1.48 Billion | $796.97 Million | -$196.08 Million | 1.85x | N/A |
| 2025 | $1.09 Billion | $757.26 Million | -$99.43 Million | 1.44x | N/A |
Competitor Companies of EVO by Market Capitalization
Companies near Evotec SE ADR in the global market cap rankings as of September 18, 2026. Review Evotec SE ADR tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Evotec SE ADR by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #519 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #633 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #640 globally with a market cap of $43.16 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.62 Billion USD ( CN¥277.61 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #519 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #633 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #640 | GALDERMA GROUP AG | NYSE:GALDY | $43.16 Billion | $37.02 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.62 Billion | CN¥43.52 |
Evotec SE ADR Historical Marketcap From 2015 to 2026
Between 2015 and today, Evotec SE ADR's market cap moved from $801.88 Million to $ 578.99 Million, with a yearly change of 3.69%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $578.99 Million | -47.08% |
| 2025 | $1.09 Billion | -25.96% |
| 2024 | $1.48 Billion | -64.54% |
| 2023 | $4.17 Billion | +44.99% |
| 2022 | $2.87 Billion | -65.94% |
| 2021 | $8.44 Billion | +29.45% |
| 2020 | $6.52 Billion | +42.78% |
| 2019 | $4.56 Billion | +29.05% |
| 2018 | $3.54 Billion | +24.08% |
| 2017 | $2.85 Billion | +106.17% |
| 2016 | $1.38 Billion | +72.43% |
| 2015 | $801.88 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of Evotec SE ADR was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.15 Billion USD |
| MoneyControl | $1.15 Billion USD |
| MarketWatch | $1.15 Billion USD |
| marketcap.company | $1.15 Billion USD |
| Reuters | $1.15 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Evotec SE ADR
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more